The Drug Discovery and Development Segment is Expected to dominate the Market Growing with the Highest CAGR of 10.5%

As per an article published by National Center for Biotechnology Information NCBI on March 2019, the recent breakthroughs of iPSCs researches have enabled to reach 100% efficiency in generating both mouse and human cells with single factor. According to the Frontiers Media S.A. journal published on February 2015, the IPSCs are applied with technological advantages such as ethical issues being eliminated by the use of IPSCs, reduced chances of immune-rejection, throughput screenings to predict toxicity, lowering the risk and cost of clinical trials, and consistent phenotype availabilities made possible with IPSC for disease modelling. The patient-specific induced pluripotent stem cells are used for modelling cardiovascular diseases, and differentiated stem cells are used in drug screening. Therefore, the emerging technological advantages of iPSCs are driving the global induced pluripotent stem cells market growth.

Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/global-induced-pluripotent-stem-cells-market

Data Bridge Market Research analyses that the induced pluripotent stem cells (iPSCs) market is expected to grow at a CAGR of 9.9% in the forecast period of 2022 to 2029 and is expected to reach USD 2,081.08 million by 2029. Induced pluripotent stem cells (iPSCs) API intermediates market needs great involvement of contract research organizations and contract manufacturing organizations to provide effective intermediates, which can cater to the needs of patients suffering from several kinds of chronic diseases. This signifies that an increasing number of contract research organizations and contract manufacturing organizations is acting as an opportunity for the global induced pluripotent stem cells (iPSCs) market growth.

Surge in Adoption of Stem Cell Therapy globally is expected to drive the market's growth rate

The developing countries have been reported to adopt stem cell treatment, paving the way for the companies engaged in induced pluripotent stem cells producers to grow in the emerging market significantly. Induced pluripotent stem cell offers the perfect solution where there is need for tissue and organ transplantation owing to its ability to differentiate between specific cell types required for treating diseased tissues. The successful introduction of induced pluripotent stem cell therapy for neurodegenerative diseases is a turning point in the field. These therapies do not only focus on detaining the progression of irrecoverable neuro-degenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis (MS), but are also focused on completely treating such disorders. The growing adoption of stem cell based therapies to treat various diseases is propelling the growth of the market. For instance, In November, 2019, BioMed Central Ltd, Springer Nature announced in their article that generation of safe and clinical grade induced pluripotent stem cells prepared from episomal vectors are routinely employed by the Center for iPS Cell Research and Application (CiRA) at the Kyoto University in Japan, the first center dedicated to develop iPSCs for scientific and therapeutic applications-like therapies. Stem cell therapies using iPSCs are used in a number of diseases including diabetes, ocular diseases, and neural diseases which are acting as a driver for the growth of the induced pluripotent stem cells market.

Report Scope and Market Segmentation

Segment Analysis:

Global induced pluripotent stem cells (iPSCs) market is categorized into six notable segments based on the cell source, type, product, applications, end users and distribution channel.

• On the basis of cell source, the global induced pluripotent stem cells (iPSCs) market is segmented into skin cells and blood cells. In 2022, skin cells segment is expected to dominate the market growing with the highest CAGR of 10.0% in the forecast period of 2022 to 2029 as the obtaining skin cells such as fibroblasts and keratinocytes are less invasive, less painful and easily obtainable.
• On the basis of type, the global induced pluripotent stem cells (iPSCs) market is segmented into human IPSCs and mouse IPSCs. In 2022, human IPSCs segment is expected to dominate the market growing with the highest CAGR of 10.5% in the forecast period of 2022 to 2029 as human somatic cells are widely used in cell therapies, disease modelling, and drug discovery and among more as controls.
• On the basis of product, the global induced pluripotent stem cells (iPSCs) market is segmented into instruments, consumables and kits and services. In 2022, consumables and kits segment is expected to dominate the market growing with the highest CAGR of 10.8%

The consumables and kits segment is expected to dominate the market growing with the highest CAGR of 10.8%

In 2022, consumables and kits segment is expected to dominate the market growing with the highest CAGR of 10.8% in the forecast period of 2022 to 2029 due to wide usage of induced pluripotent stem cell kits in toxicology testing

• On the basis of application, the global induced pluripotent stem cells (iPSCs) market is segmented into academic research, regenerative medicine, cellular therapy, toxicology screening, drug discovery and development, disease modelling, stem cell banking, 3D bioprinting and others. In 2022, drug discovery and development segment is expected to dominate the market growing with the highest CAGR of 10.5% in the forecast period of 2022 to 2029 as stem cells are gaining more attention in discovery new therapeutic options for arising various chronic and infectious diseases.
• On the basis of end-users, the global induced pluripotent stem cells (iPSCs) market is segmented into biotechnology and pharmaceutical companies, research laboratories, diagnostic laboratories and others. In 2022, biotechnology and pharmaceutical companies segment is expected to dominate the market growing with the highest CAGR of 11.8% in the forecast period of 2022 to 2029 as they manufacture and develop various stem cell kits and service technology using induced pluripotent stem cells for various diseases.
• On the basis of distribution channel, the global induced pluripotent stem cells (iPSCs) market is segmented into direct tender and retail sales. In 2022, direct tender segment is expected to dominate the market growing with the highest CAGR of 10.8% in the forecast period of 2022 to 2029 due to the stable quality maintenance of products directly from manufacturing units.

Major Players

Data Bridge Market Research recognizes the following companies as the major induced pluripotent stem cells (iPSCs) market players in induced pluripotent stem cells (iPSCs) market are BD (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Organogenesis Inc. (U.S.), Vericel Corporation (U.S.), ANTEROGEN. CO., LTD. (South Korea), VistaGen Therapeutics, Inc. (U.S.), American Cryostem Corporation (U.S.), PromoCell GmbH (Germany), Sartorius AG (Germany), ViaCyte, Inc. (U.S.), STEM CELL Technologies, Inc. (Canada), Takeda Pharmaceutical Company Limited (Japan), DAIICHI SANKYO COMPANY, LIMITED (Japan), Bio-Techne (U.S.), REPROCELL Inc. (India), Catalent, Inc. (U.S.), Mesoblast Ltd (Australia), Astellas Pharma Inc. (Japan), FUJIFILM Holdings Corporation (Japan).

Market Development

• In August 2020, Caildi Biotherapeutics, Inc, announced that it has received FDA approval for investigational new drug application for the treatment of COVID 19 and pneumonia using stem cell therapy
• In December 17, 2020, REPROCELL announced in its website that it launched latest new service called "Personal iPS" to generate individual-specific pluripotent stem cell (iPSC). Alongside, the company also launched a new B2C website to promote the service globally. This enhanced their company's revenue over market
• In September, 2020, Applied StemCell, Inc. announced in its website that the company signed an agreement of partnership with ERS Genomics Limited which is formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP). This helped the company in enhancing its current research by incorporating both research facilities for better research outcome
• In November 2021, Shoreline Biosciences, Inc. announced that the company financed USD 140 Million for advancing the pipeline of next generation cell immunotherapies. This thereby accelerated the growth of Shoreline's pipeline of induced pluripotent stem cell based cell immunotherapies for seriously ill patients with better manufacturing capabilities.
• In November 16, 2021, the Ncardia, a leader in developing stem cell-based drug discovery solutions, partnered with Kiniciti, a U.S.-based investment platform and secured USD 60 million in capital to strengthen the cell and gene therapy ecosystem. They also mentioned through this investment and partnership both companies can be strong and successful global leader in induced pluripotent stem cell market.

Regional Analysis

Geographically, the countries covered in the induced pluripotent stem cells (iPSCs) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in induced pluripotent stem cells (iPSCs) market during the forecast period

North America dominated the induced pluripotent stem cells (iPSCs) market owing to the increasing usage of stem cell technology. North America will continue to dominate the induced pluripotent stem cells (iPSCs) market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the high adoption of stem cell sources for better therapies.

Asia-Pacific is estimated to be the fastest growing region in induced pluripotent stem cells (iPSCs) market

Asia-Pacific is expected to grow during the forecast period due to the increasing number of biotechnology centers and research activities in this region. In addition to this, growing presence of major market players and rising disposable income are expected propel the market's growth rate in this region.

For more detailed information about the induced pluripotent stem cells (iPSCs) market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-induced-pluripotent-stem-cells-market